Webinar Summary
Patients with inherited cardiomyopathy need therapies tested in models that behave like human heart muscle. BAG3 variants account for up to 5 percent of genetically resolved dilated cardiomyopathy, but recapitulating that phenotype in vitro requires a readout that measures force, yet most iPSC-based screens stop at calcium transients and monolayer morphology
On October 28 at 8 AM PT, Curi Bio and Greenstone Biosciences present jointly generated data on a human iPSC-derived cardiomyocyte line carrying a heterozygous BAG3 frameshift mutation, cast as 3D engineered heart tissues (EHTs) and profiled on Mantarray™ and Nautilai™. The BAG3-mutant tissues were hypocontractile, failed to entrain to electrical pacing, and required more external calcium to generate force, a functional signature consistent with the reduced ejection fraction reported for the donor.
Join Dr. Thomas Leahy (Curi Bio) and Dr. Todd Herron (Greenstone Biosciences) for a data-rich session on what 3D contractility and pharmacology add to genotype-anchored cardiac disease modeling, and learn how to put Greenstone lines to work on Curi Bio platforms.
Force Is the Phenotype. See how BAG3-mutant EHTs reported a dilated cardiomyopathy-like functional deficit, including reduced twitch force and failure to follow pacing, that monolayer assays cannot measure directly.
Multiple Functional Challenges, One Plate of Tissues. Learn how a single EHT cohort supported a calcium titration, a verapamil dose response, and a beta-adrenergic challenge across a 28-day culture.
Genotype to Function, Without the Animal. Hear how patient-derived iPSC lines and 3D engineered tissues combine into a human-relevant NAM strategy for cardiac disease modeling and safety.
Access the Biobank. Greenstone shares how its human iPSC biobank, built from more than 2500 donors, gives programs access to disease-relevant and rare disease lines.
Run It as a Service. Curi Engine™ Research Services profiles Greenstone iPSC-CM lines as EHTs on Mantarray and Nautilai, so teams can generate this data without building the platform in house.
Speaker Details
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Leahy is a Field Applications Scientist at Curi Bio with a background in musculoskeletal and cardiovascular research, biomechanics, and 3D tissue engineering. He supports the adoption of Curi Bio's technologies by collaborating with internal scientists and partnering directly with customers to expand applications across cardiac, skeletal muscle, and neuromuscular research. He is a co-author on the BAG3 study presented in this session.
Dr. Todd Herron
Director, hiPSC BioBank at Greenstone Biosciences
Dr. Todd Herron
Director, hiPSC BioBank at Greenstone Biosciences
Dr. Herron directs the hiPSC BioBank at Greenstone Biosciences, where he builds human-relevant cell models for disease modeling, toxicity screening, and regenerative applications. He earned his PhD in cardiac physiology at the University of Missouri, completed a postdoctoral fellowship at King's College London, and spent 20 years on the faculty at the University of Michigan, where he founded the Frankel Cardiovascular Regeneration Core Laboratory. His work spans cardiac biology from single cells to integrated physiology, with a current focus on iPSC-derived models as alternatives to animal studies.
Register Now to Secure Your Spot
Submit the form below to register for this live webinar + Q&A session. Registration will close 48 hours before the event.
Please contact us with any questions or concerns.